Clinical Trial Update: Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated the efficacy and safety of enteric-coated mycophenolate sodium in heart transplant recipients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Enteric-coated mycophenolate sodium (mycophenolate sodium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS | Phase 3 | Status: COMPLETED